Patients with neonatal lupus erythematosus (NLE) often have congenital heart block with or without heart failure and are born to mothers who have anti-SS-A and/or anti-SS-B antibodies. NLE has been considered to result from the placental transmission of maternal autoantibodies into the fetal circulation causing myocardial damage. We report a case of NLE with congenital heart block who had undergone pacemaker implantation at the age of 17, and then developed dilated cardiomyopathy (DCM) at the age of 19, which is much later than in most other cases. The patient's mother was positive for anti-SS-A and anti-SS-B antibodies, whereas the patient was negative for both anti-SS-A and anti-SS-B antibodies. There were some autoantibodies against cell surface antigens of cardiac myocytes in the serum from the patient, and annexin A6 was identified as one of the autoantigens. This is the first report demonstrating that annexin A6 is involved in the myocardial injury in patients with NLE. The results indicate that inhibition of annexin A6 function may prevent autoantibody-mediated myocardial injury in at least some cases of DCM. (Int Heart J 2007; 48: 407-415) 
PATIENTS with neonatal lupus erythematosus (NLE) are born to mothers who have anti-SS-A and/or anti-SS-B antibodies. They often have congenital heart block with or without heart failure, and cutaneous lesions, which subsequently disappear about 6 months after birth. 1) Approximately 200 patients have been reported, and half of them had congenital heart block. NLE has been considered to result from the placental passage of maternal autoantibodies into the fetal circulation causing damage to an otherwise normally developed heart. An inflammatory phase of cardiac injury is observed in the fetus heart. Because most patients with this syndrome die young, there have been few reports presenting patients who have lived until adulthood. About half of the patients with NLE undergo permanent pacemaker implantation before 3 months of age, and a majority have pacemaker implantation before 10 years of age. 2) Here, we report a case of NLE with congenital heart block who had pacemaker implantation at the age of 17, which is much later than usual, and then developed dilated cardiomyopathy (DCM). The mother was positive for anti-SS-A and anti-SS-B antibodies, whereas the patient was negative for both anti-SS-A and anti-SS-B antibodies. We found that there were some autoantibodies against cell surface antigens of cardiac myocytes in serum from the patient, and identified annexin A6 as one of the autoantigens.
CASE REPORT
The patient was a 37-year-old Japanese man in whom abnormal heart sounds were detected at 36 weeks of gestation. He was born at 43 weeks of gestation. At birth, cyanosis, poor sucking, and poor weight gain were observed. He suffered from pneumonia at 7 months of age. At 14 months, he was brought to our hospital because of coughing and fever. Abnormal heart sounds, a harsh holo-systolic murmur (Levine 3rd degree), and a high-pitched diastolic murmur (Levine 2nd degree) were found. ECG showed complete AV block. At 19 months, angiography revealed patent ductus arteriosus (PDA). Closure of the PDA was performed at 24 months and he was then started on oral digoxin. His heart rate was between 70 and 85 beats per minute, and the cardiothoracic ratio (CTR) was about 52%. He could exercise normally, with the exception of running and swimming. At 17 years of age, a pacemaker was implanted on DDD mode because of complete heart block. At 19, he suffered from coughing and a low grade fever. Then, general malaise, orthopnea, nausea, and vomiting occurred as the symptoms worsened. He was urgently hospitalized because of the first episode of heart failure. At that time, 3 rd and 4 th heart sounds were heard. Peripheral venous pressure (PVP) was 20 cmH 2 O. His C-reactive protein (CRP) level and white blood cell (WBC) count were elevated (Table I) sample showed interstitial fibrosis, endocardial thickening, and contraction necrosis. No obvious cell infiltration was found. These findings were compatible with those of DCM. He received O 2 inhalation and was medicated with intravenous furosemide and digoxin. His CRP level and WBC count soon decreased to within normal ranges. The immunological data of the patient and his mother are summarized in Table II . Although his speckled antinuclear antibody (ANA) test result was mildly elevated, other immunological data were within normal ranges. He had no symptoms suggestive of autoimmune diseases. His mother was positive for anti-SS-A and anti-SS-B antibodies as well as homogeneous and speckled ANA. Her serum levels of IgA and IgG were elevated. She had no symptoms suggestive of autoimmune diseases. He was discharged after 2 months of hospitalization. However, he soon experienced exertional dyspnea, orthopnea, rapid gain of body weight, and he was rehospitalized because of worsening of his congestive heart failure. He was medicated orally with furosemide (120 mg/day), spironolactone (50 mg/day), enalapril (5 mg/day), and digoxin (0.25 mg/day). Symptom- limited exercise testing with expired gas analysis showed that his peak oxygen uptake was 18.2 mL/min/kg (51% of predicted normal values) and his anaerobic threshold was 13.9 mL/min/kg (71% of predicted normal values), suggesting that he had severe exercise intolerance and severe congestive heart failure. Oral administration of metoprolol, a β-blocker, was started and was increased to the dosage of 60 mg per day. His heart rate decreased from 90 to 65 beats per minute, and the CTR also decreased from 54% to 49%. His symptoms of heart failure were dramatically improved. This was associated with a substantial improvement of peak oxygen uptake and anaerobic threshold. After the initiation of β-blocker therapy, the number of hospitalizations decreased, and his exercise tolerance remained stable. He was able to work in an office for 3 years. Figure 1 shows the results of echocardiography in this period. However, his symptoms gradually deteriorated when he was 29-years-old, and he was hospitalized again because of deterioration of his heart failure. He was subsequently hospitalized 7 times due to heart failure. At present, his New York Heart Association (NYHA) functional classification is 3rd degree and he has severe exercise intolerance under oral administration of carvedilol (a β-blocker, 15 mg/day), candesartan (an angiotensin II receptor blocker, 8 mg/day), furosemide (120 mg/day), and spironolac- tone (25 mg/day).
METHODS
Because it was strongly suggested that some autoantibodies may be playing a role in myocardial injury in this patient, we investigated whether there were autoantibodies against some antigens of cardiac myocytes in serum from the patient and identified the antigens expressed on the surface of cardiac myocytes. This study was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association, and was approved by the Ethics Committee of the University of Tokyo Hospital. The patient gave written informed consent after receiving full explanations of the purpose, nature, and risk of all procedures used. Primary cultures of ventricular cardiac myocytes were prepared from neonatal rats as described elsewhere.
3) The myocytes were cultured for 3 days and washed in phosphate buffered saline (PBS). The plasma membrane fraction of the cardiac myocytes was prepared as described elsewhere, 4) subjected to 2-D gel electrophoresis, and then transferred onto polyvinylidene difluoride transfer membranes (NEN Research Products). The transfer membranes were blocked with 1% BSA and then incubated overnight at room temperature with 10-fold diluted sera from the patient or an age-and sex-matched healthy control. After being incubated with biotinylated anti-human IgG (EY Laboratories, Inc., CA, USA), and then Vectastrain ABC-AP reagent (Vector Laboratories, Inc., CA, USA), the blot was developed with a chemiluminescence detection kit (Phototope-Star Detection Kit, New England Biolabs, MA, USA). The same plasma membrane fraction was also subjected to 2-D gel electrophoresis followed by staining with Coomassie brilliant blue. The spots corresponding to the reaction products by Western blots were excised and in gel digested, and then analyzed by mass spectrometry (MS). The procedures for 2-D gel electrophoresis, in gel digestion, and MS analysis were as described elsewhere. Figure 2 shows the results of Western blot analysis of a healthy control subject (panel A) and the patient (panel B). There were almost no spots that reacted with the serum from a healthy control subject (panel A), whereas there were several spots that reacted with the patient's serum (panel B). LC-MS/MS analysis identified 2 of these protein spots indicated by arrows 1 and 2 as annexin A6 and vimentin, respectively (panel B). The other spots could not be identified as known proteins.
5)

RESULTS
DISCUSSION
Patients with NLE often have congenital heart diseases such as atrial septal defect and an abnormality of the great arteries, such as PDA, which was found in our patient. However, at least 10% of NLE patients with heart block develop heart failure due to myocardial injury by the disease process. 6) These patients generally develop heart failure at birth or very shortly after birth. Taylor-Albert, et al 7) reported 2 cases of NLE with complete heart block who had pacemaker implantation shortly after birth and developed heart failure due to DCM at 8 and 4 months after birth, respectively. The authors speculated that the presence of high levels of maternal anti-SS-A antibody in the infant sera caused delayed heart failure. The patient in the present study had pacemaker implantation and developed heart failure at the age of 17 and 19, respectively, which are much later than the usual course of NLE. Furthermore, although the mother of this patient was positive for anti-SS-A and anti-SS-B antibodies as well as homogenous and speckled ANA, the patient himself did not have either anti-SS-A or anti-SS-B antibodies, at least when he developed heart failure.
It was reported that antibodies in the sera from mothers of children with congenital heart block that were capable of crossing the placenta reacted at significantly higher rates with fetal myocardial tissues than antibodies in the sera from control subjects. 8) In addition, there was deposition of immunoglobulin and complement components in all cardiac tissues of these infants, strongly suggesting the role of maternal antibodies in the development of fetal heart block. 8) In fact, Xiao, et al 9) demonstrated that the sera from mothers containing anti-SS-A and anti-SS-B antibodies whose children had congenital heart block significantly inhibited Land T-type Ca 2+ channels expressed in Xenopus oocytes. With respect to the roles of autoantibodies in DCM, sera from DCM patients have been shown to significantly decrease isoproterenol-stimulated L-type Ca 2+ currents in isolated rabbit cardiac myocytes.
10) Therefore, it is strongly suggested that autoantibody-mediated myocardial injury was involved in the development of complete heart block as well as DCM in the present patient and that autoantibodies other than anti-SS-A and anti-SS-B played a critical role in this process because the patient did not have either antibody and the onset of these conditions was extremely late. In the present study, we have showed that this patient had circulating autoantibodies against annexin A6 and vimentin. Vimentin, like desmin, is a member of the intermediate filament family proteins. They form the cytoskeletal structure along with microtubules and actin microfilaments, and are thought to play an important role in supporting and anchoring the organelles in the cytosol. Therefore, it seems unlikely that a circulating antivimentin antibody can significantly affect myocardial contractile function. Annexins are ubiquitous proteins characterized by a conserved C-terminal domain with Ca 2+ binding sites and a variable N-terminal domain. In general, the C-terminal domain consists of 4 repeats containing an α-helix structure, except for Annexin A6 which has 8 repeats. Annexin A6 is the most abundant annexin in the heart and is constitutively expressed in cytosol and plasma membrane. Ca 2+ binding leads to conformational changes of the structure, high affinity for phospholipids, and relocation to plasma and nuclear membranes followed by membrane insertion. Annexin A6 has been suggested to act as a regulator of the Na + /Ca 2+ exchanger and/or SR Ca 2+ -ATPase. 11, 12) Annexin A6 knockout has been found to induce faster changes in Ca 2+ transient and increased contractility, 13) whereas overexpression of annexin A6 has been shown to reduce contraction and relaxation of cardiac myocytes, leading to DCM. 14) Therefore, annexin A6 has been proposed to be a negative regulator of cardiac function. These data suggest that a circulating antiannexin A6 antibody may bind annexin A6 on the surface of cardiac myocytes and stimulate its function, resulting in the suppression of myocardial contractility. This is the first report demonstrating that annexin A6 was involved in myocardial injury in patients with NLE. The present findings indicate that inhibition of annexin A6 function can prevent autoantibody-mediated myocardial injury in at least some cases of DCM.
